Document is current
Any future updates will be listed below
-
Authors
Strell, Carina
Rodríguez-Tomàs, Elisabet
Östman, Arne
-
Funding
Funding for this research was provided by:
Trond Mohn stiftelse (TMS2022STG01)
Cancerfonden (210401FE, 211749Pj, 1234/2021)
Vetenskapsrådet (2022-01151, 2222/2020)
Karolinska Institute
- License Information
-
More Information
Article History
Received: 7 February 2024
Accepted: 12 June 2024
First Online: 9 July 2024
Declarations
:
: AÖ and CS hold a patent on PDGFRB as biomarker for radiotherapy sensitivity in breast cancer, and are co-founders of TECKNET AB.
